A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Erika Hamilton, MD
Tennessee Oncology
Principal Investigator - Nicole Concin, MD
KEM Kliniken Essen Mitte Evang. Huyssens-Stiftung
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical University of Innsbruck
Innsbruck, Austria
- Saint Luc Univerisity Hospital
Brussels, Belgium
- University Hospital Ghent
Ghent, Belgium
- University Hospitals Leuven, Campus Gasthuisberg
Leuven, Belgium
- University Hospital Carl Gustav Carus
Dresden, Germany
- Kliniken Essen-Mitte
Essen, Germany
- University Hospital Mannhein
Mannheim, Germany
- Polyclinic S. Orsola-Malpighi
Bologna, Italy
- National Cancer Institute -Irccs "fondazione G. Pascale
Naples, Italy
- Foundation Irccs Hospital Agostino Gemelli
Rome, Italy
- University Hospital Reina Sofia
Córdoba, Andalusia, Spain
- University Hospital Vall D'Hebron
Barcelona, Spain
- la Paz University Hospital
Madrid, Spain
- Navarra University Clinic
Madrid, Spain
- Ucla Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
- Uc San Diego Moores Cancer Center
San Diego, California, United States
- Anschutz Cancer Pavilion
Aurora, Colorado, United States
- Florida Cancer Specialists
Sarasota, Florida, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Nyu Langone Laura and Isaac Perlmutter Cancer Center
New York, New York, United States
- Duke University School of Medicine
Durham, North Carolina, United States
- Ohio State University Wexner Medical Center
Columbus, Ohio, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Magee-Womens Hospital of Upmc
Pittsburgh, Pennsylvania, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Jul 2019
- Primary completion
- 31 Jul 2023
- Completion
- 31 Jan 2024
- Last update posted
- 20 Dec 2022
- Registered enrollment
- 227
- Registry id
- NCT04042116
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.